Developing a gut epithelial shield for patients with colitis
Revolutionising gut health
ThirtyFiveBio are developing a gut epithelial shield for patients with ulcerative colitis. GPR35 inhibition protects gut epithelial cells under attack by inflammatory factors in colitis.
Challenges of treating ulcerative colitis
Even state-of-the-art anti-inflammatory medicines display limited benefit for ulcerative colitis patients, with most patients being non-responders, and for those that do respond, many relapse.
New orthogonal treatments are required that target underlying disease causality, therefore improving immediate and long-term disease resolution.
The future of treatment
Protecting the gut epithelium, by reducing epithelial dysfunction and damage seen in patients, holds the promise of revolutionising outcomes for IBD patients and disrupting IBD treatment paradigms.
ThirtyFiveBio are developing a gut epithelial shield for patients with ulcerative colitis.
Innovative approach to treat ulcerative colitis
.png)
Correct epithelial dysfunction
.png)
Raise current response ceiling
Enhance patient outcomes
